Anticholinergics urinary incontinence with

Siegler EL, Reidenbe M Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol 77ier(2004) 75,484-8. 

Oxytrol is a three- or four-day patch used for the treatment of urinary incontinence that was recently approved by the FDA. It delivers the active ingredient oxybutynin. Oxybutynin is an antispasmotic and anticholinergic agent with a molecular weight of 357. Oxybutynin is considered to be a lipophilic drug. Oxytrol is a matrix-type patch with a surface area of 39 cm2 and contains 36 mg of oxybutynin. Oxytrol has an in vivo delivery rate of approximately 3.9mg/day. 

As noted previously, anticholinergic agents have undergone something of a renaissance due to their use as drugs to treat urinary incontinence. The synthesis of one of these muscarinic antagonsists starts with the classic... 

Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001 166 140-145. 

Darifenacin is an anticholinergic agent that blocks muscarinic cholinergic receptors. Darifenacin is indicated in treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. 

Oxybutynin chloride is an anticholinergic that increases bladder capacity, diminishes frequency of uninhibited contractions of detrusor muscle and delays initial desire to void. It is indicated in the treatment of symptoms of bladder instability associated with voiding in patients with uninhibited and reflex neurogenic bladder (e.g., urinary leakage, dysuria) and treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. 

Urinary retention, incontinence, or dysuria can occasionally occur with neuroleptic drugs that have marked anticholinergic effects. 

---